% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • pharmaman58 pharmaman58 Jul 11, 2013 5:54 PM Flag


    1. By my analysis, sarcoidosis is another indication showing promise of 300-400 scripts per quarter at 4-6 vials per script. Also opens up the pulmonologist market, who are similar to rheumatologists in that they can prescribe for a number of autoimmune/inflammatory disorders--and all will be 4-6 vial scripts in my opinion.
    2. Rheumatology related scripts living up to their potential.
    3. Analysts starting to raise target prices $5 to $8.
    4. Sounds like a strong Q2 to me, leading into a knockout 2H.

    The spike today was a bit disappointing given the level and immediacy of the news. But give it time and get rewarded. If we know anything about QCOR, it is this: immediate gratification is an elusive commodity.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies